

PRESS RELEASE

Stockholm, April 26, 2013



Resolutions from Sobi's Annual General Meeting (AGM)

The Swedish Orphan Biovitrum AB's (publ) (Sobi) AGM convened earlier today in Stockholm and voted in favour of the resolutions proposed at the meeting, including:

Adoption of the profit and loss statements and balance sheet and discharge of liability

The AGM adopted the income statements and the balance sheets and approved the proposal to carry forward the retained profits of SEK 4,659,221,805.

The board members and the chief executive officer were discharged from liability for the financial year 2012.

Election of Board of Directors, remuneration to the Directors and election of Auditor

The ordinary board members Adine Grate Axén, Matthew Gantz, Bo Jesper Hansen, Lennart Johansson, Helena Saxon, Hans GCP Shikan and Hans Wigzell were re-elected and Bo Jesper Hansen was re-elected chairman of the Board.

The AGM approved the compensation to the Board in accordance with the nomination committee's proposal.

PricewaterhouseCoopers AB was re-elected auditor of Sobi until the end of the annual general meeting 2014.

Nomination Committee

The AGM approved the proposed instructions and charter for the nomination committee.

Principles for remuneration for the management, long-term incentive program and transfer of own shares

The AGM approved the proposed guidelines for remuneration for the management.

The AGM also approved the Board's proposal regarding the implementation of a long-term incentive program, and hedging arrangements in respect of the program including a directed issue of no more than 754,912 series C shares, authorisation for the Board to decide on a repurchase of all issued series C shares and transfers of no more than 1,719,238 own common shares to program participants.

The Board's proposal regarding transfer of no more than 135,082 own common shares on the stock exchange for the purpose of covering certain payments, mainly social security contributions, that may occur in relation to the Share Program 2010, was also approved by the AGM.

For full details on each proposal adopted by the AGM please refer to www.sobi.com.

About Sobi

Sobi is an international specialty healthcare company dedicated to rare diseases. Our mission is to develop and deliver innovative therapies and services to improve the lives of patients. The product portfolio is primarily focused on Inflammation and Genetic diseases, with three late-stage biological development projects within Haemophilia and Neonatology. We also market a portfolio of specialty and rare disease products for partner companies. Sobi is a pioneer in biotechnology with world-class capabilities in protein biochemistry and biologics manufacturing. In 2012, Sobi had total revenues of SEK 1.9 billion (€ 215 M) and about 500 employees. The share (STO: SOBI) is listed on NASDAQ OMX Stockholm. More information is available at www.sobi.com

For more information please contact

Media relations

Oskar Bosson, Head of Communications

T: +46 70 410 71 80

oskar.bosson@sobi.com

Investor relations

Jörgen Winroth, Vice President, Head of Investor Relations

T: +46 8 697 20 00

jorgen.winroth@sobi.com

The information was released for public distribution on April 26, 2013 at 18:30 CET.